<i>TP53</i> status and impact on AML prognosis within the ELN 2022 risk classification-Reference-Cited by-同舟云学术

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Published:2023-12-07 Issue:23 Volume:142 Page:2029-2033
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Fleming Shaun¹²,Tsai Xavier Cheng-Hong³,Morris Rhiannon⁴^ORCID,Hou Hsin-An³,Wei Andrew H.⁴⁵^ORCID

Affiliation:

1. 1Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

2. 2Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia

3. 3Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

4. 4Division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Melbourne, Australia

5. 5Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Australia

Abstract

Abstract This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of −7, −5/del(5q), −17/abn(17p), complex karyotype/monosomal karyotype, or myelodysplasia-related gene mutations with/without mutated TP53.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/142/23/2029/2159682/blood_bld-2023-020855-main.pdf

Reference8 articles.

1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data;Arber;Blood,2022

2. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome;Rücker;Blood,2012

3. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome;Grob;Blood,2022

4. Specific subtype distribution with impact on prognosis of TP53 single hit and double hit events in AML and MDS;Stengel;Blood Adv,2023

5. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML;Weinberg;Blood Adv,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment;Frontiers in Pharmacology;2024-08-05

2. Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and molecular characteristics;Leukemia & Lymphoma;2024-07-25

3. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease;British Journal of Haematology;2024-05-09

4. TP53 in MDS and AML: Biological and clinical advances;Cancer Letters;2024-04

5. Venetoclax Resistance in Acute Myeloid Leukemia;Cancers;2024-03-08